Long-term effects of cladribine tablets treatment on cognition, relapses, MRI, and safety outcomes in patients with relapsing multiple sclerosis: 4-year results from the CLARIFY-MS Extension study

被引：0
|
作者：
Selmaj, Krzysztof [1 ,2 ]
Langdon, Dawn [3 ]
Brochet, Bruno [4 ]
Solari, Alessandra [5 ]
Havrdova, Eva Kubala [6 ,7 ]
Patti, Francesco [8 ,9 ]
Piehl, Fredrik [10 ]
Smyk, Andrzej [11 ]
Lehn, Annette [11 ]
Nolting, Axel [11 ]
Montalban, Xavier [12 ]
Lechner-Scott, Jeannette [13 ,14 ]
机构：
[1] Ctr Neurol, Lodz, Poland
[2] Univ Warmia & Mazury, Dept Neurol, Olsztyn, Poland
[3] Royal Holloway Univ London, Dept Psychol, Egham, Surrey, England
[4] Univ Bordeaux, INSERM U 1215, Bordeaux, France
[5] Fdn IRCCS Ist Neurol Carlo Besta, Unit Neuroepidemiol, Milan, Italy
[6] Charles Univ Prague, Med Fac 1, Dept Neurol, Prague, Czech Republic
[7] Ctr Clin Neurosci, Prague, Czech Republic
[8] Univ Catania, Dept Med & Surg Sci & Adv Technol, GF Ingrassia, Catania, Italy
[9] Univ Catania, Azienda Osped Univ Policlin G Rodolico San Marco, Catania, Italy
[10] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden
[11] Merck Healthcare KGaA, Darmstadt, Germany
[12] Univ Hosp Vall dHebron, Dept Neurol Neuroimmunol, Ctr Multiple Sclerosis Catalonia Cemcat, Barcelona, Spain
[13] Univ Newcastle, Newcastle, NSW, Australia
[14] John Hunter Hosp, Div Neurol, Newcastle, NSW, Australia
来源：
MULTIPLE SCLEROSIS JOURNAL | 2024年 / 30卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P846/1650
引用
收藏
页码：655 / 657
页数：3
相关论文
共 50 条
  • [41] Long-term (>7-year) efficacy and safety data from a phase II extension study of fingolimod in relapsing multiple sclerosis
    Montalban, X.
    Comi, G.
    Antel, J.
    O'Connor, P.
    de Vera, A.
    Cremer, M.
    Sfikas, N.
    Francis, G.
    Kappos, L.
    JOURNAL OF NEUROLOGY, 2012, 259 : S69 - S70
  • [42] Long-term safety and efficacy of daclizumab beta in relapsing–remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study
    Ralf Gold
    Ernst-Wilhelm Radue
    Gavin Giovannoni
    Krzysztof Selmaj
    Eva Kubala Havrdova
    Xavier Montalban
    Dusan Stefoski
    Till Sprenger
    Randy R. Robinson
    Sami Fam
    Jonathan Smith
    Spyros Chalkias
    Giorgio Giannattasio
    Gabriel Lima
    Wanda Castro-Borrero
    Journal of Neurology, 2020, 267 : 2851 - 2864
  • [43] CLASSIC-MS: Long-term Efficacy and Real-World Treatment Patterns for Patients with Relapsing Multiple Sclerosis who Received Cladribine Tablets in Phase III Parent Trials
    Giovannoni, Gavin
    Aydemir, Aida
    Di Cantogno, Elisabetta Verdun
    Leist, Thomas
    NEUROLOGY, 2021, 96 (15)
  • [44] The long-term safety and tolerability of high-dose interferon β-1a in relapsing-remitting multiple sclerosis:: 4-year data from the PRISMS study
    Gold, R
    Rieckmann, P
    Chang, P
    Abdalla, J
    EUROPEAN JOURNAL OF NEUROLOGY, 2005, 12 (08) : 649 - 656
  • [45] Long-term effects of natalizumab on MRI activity and clinical outcomes in Japanese patients with relapsing-remitting multiple sclerosis
    Takahiko Saida
    Qi Hao
    Michihiro Kanda
    Yumiko Tani
    BMC Neurology, 23
  • [46] Long-term effects of natalizumab on MRI activity and clinical outcomes in Japanese patients with relapsing-remitting multiple sclerosis
    Saida, Takahiko
    Hao, Qi
    Kanda, Michihiro
    Tani, Yumiko
    BMC NEUROLOGY, 2023, 23 (01)
  • [47] Long-Term (7-Year) Data from a Phase 2 Extension Study of Fingolimod in Relapsing Multiple Sclerosis
    Antel, Jack
    Montalban, Xavier
    O'Connor, Paul
    de Vera, Ana
    Cremer, Malika
    Sfikas, Nikolaos
    Comi, Giancarlo
    Kappos, Ludwig
    NEUROLOGY, 2012, 78
  • [48] Long-term efficacy of fingolimod in patients with relapsing remitting multiple sclerosis: results from the phase 3 FREEDOMS II extension study
    Reder, A. T.
    Jeffery, D.
    Goodin, D.
    Kappos, L.
    Lublin, F. D.
    Radue, E. W.
    Rammohan, K.
    Vollmer, T.
    Agius, M. A.
    Stites, T.
    Li, B.
    Cappiello, L.
    von Rosenstiel, P.
    Calabresi, P. A.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 510 - 511
  • [49] Safety and Tolerability of Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS): Final Results from the 120-Week Phase IIIb Extension Trial to the CLARITY Study
    Cook, Stuart
    Comi, Giancarlo
    Rieckmann, Peter
    Rammohan, Kottil
    Soelberg-Soerensenn, Per
    Vermersch, Patrick
    Martin, Emily
    Dangond, Fernando
    Giovannoni, Gavin
    NEUROLOGY, 2016, 86
  • [50] Safety and tolerability of cladribine tablets in patients with relapsing-remitting multiple sclerosis (RRMS): final results from the 120-week Phase IIIb extension trial to the CLARITY study
    Cook, S.
    Comi, G.
    Rieckmann, P.
    Rammohan, K.
    Soelberg-Sorensen, P.
    Vermersch, P.
    Martin, E.
    Dangond, F.
    Giovannoni, G.
    SWISS MEDICAL WEEKLY, 2016, 146 : 78S - 78S
12345